Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 26:13:1273019.
doi: 10.3389/fcimb.2023.1273019. eCollection 2023.

Engineering a dual vaccine against COVID-19 and tuberculosis

Carlyn Monèt Guthrie  1   2 , Xuejuan Tan  1   2 , Amber Cherry Meeker  1   2 , Ashton Elisabeth Self  1   2 , Lin Liu  2   3 , Yong Cheng  1   2
Affiliations

Engineering a dual vaccine against COVID-19 and tuberculosis

Carlyn Monèt Guthrie et al. Front Cell Infect Microbiol. .

Abstract

The COVID-19 pandemic, caused by SARS-CoV-2 virus, has been one of the top public health threats across the world over the past three years. Mycobacterium bovis BCG is currently the only licensed vaccine for tuberculosis, one of the deadliest infectious diseases in the world, that is caused by Mycobacterium tuberculosis. In the past decades, recombinant M.bovis BCG has been studied as a novel vaccine vector for other infectious diseases in humans besides tuberculosis, such as viral infections. In the current study, we generated a recombinant M. bovis BCG strain AspikeRBD that expresses a fusion protein consisting of M. tb Ag85A protein and the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein using synthetic biology technique. Our results show that the recombinant M. bovis BCG strain successfully expressed this fusion protein. Interestingly, the recombinant M. bovis BCG strain AspikeRBD significantly induced SARS-CoV-2 spike-specific T cell activation and IgG production in mice when compared to the parental M.bovis BCG strain, and was more potent than the recombinant M.bovis BCG strain expressing SARS-CoV-2 spike RBD alone. As expected, the recombinant M. bovis BCG strain AspikeRBD activated an increased number of M. tb Ag85A-specific IFNγ-releasing T cells and enhanced IgG production in mice when compared to the parental M.bovis BCG strain or the BCG strain expressing SARS-CoV-2 spike RBD alone. Taken together, our results indicate a potential application of the recombinant M. bovis BCG strain AspikeRBD as a novel dual vaccine against SARS-CoV-2 and M. tb in humans.

Keywords: COVID-19; Mycobacterium bovis BCG; dual vaccine; mice; tuberculosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Generation of recombinant M. bovis BCG strains AspikeRBD and SpikeRBD. (A) Structure of the SARS-CoV-2 spike protein. SS, signal sequence; NTD, N-terminal domain; RBD, receptor-binding domain; SD1, subdomain 1; SD2, subdomain 2; TM, transmembrane anchor; IC, intracellular tail; S1, S1 subunit; S2, S2 subunit. (B) Side view of the prefusion structure of the SARS-CoV-2 spike protein with a single RBD in the up conformation (cited from Wrapp et al., 2020). (C) Schematic of the AspikeRBD and SpikeRBD engineering.
Figure 2
Figure 2
Verification of recombinant M. bovis BCG strains. (A) PCR analysis of the generated plasmids. pMV-AspikeRBD, pMV261 containing the DNA fragment encoding the fusion protein Ag85A::SpikeRBD; pMV-SpikeRBD, pMV261 containing the DNA fragment encoding the RBD domain of the SARS-CoV-2 spike protein. Negative Control, no DNA template. (B) Western blot for recombinant M. bovis BCG strains expressing AspikeRBD or SpikeRBD. Wild-type M. bovis BCG was used as a negative control.
Figure 3
Figure 3
Spike-specific T-cell response in C57BL/6 mice immunized with recombinant M. bovis BCG strains. The number of antigen-specific IFNγ-releasing T-cells in the lung and spleen was determined by ELISPOT analysis in the presence of the recombinant SARS-CoV-2 spike full protein (A) or RBD (B). Data are mean ± SD (n=3/group) and representatives of two independent experiments. Mock, unimmunized. n.s., not statistically significant; *p < 0.05, **p < 0.01 and ***p < 0.001 by two-tailed Student’s t-test.
Figure 4
Figure 4
Titration of spike RBD-specific IgG in C57BL/6 mice immunized with recombinant M. bovis BCG strains. SARS-CoV-2 spike RBD-specific IgG endpoint titers were determined using mouse serum that was collected 4 weeks after M.bovis BCG immunization. Mean reciprocal dilutions are used as the endpoint titer (log10). Data shown are the mean ± SD (n=3/group) and representative of two independent experiments. Mock, unimmunized. **p < 0.01 by two-tailed Student’s t-test.
Figure 5
Figure 5
M. tb Ag85A-specific T-cell response in C57BL/6 mice immunized with recombinant M. bovis BCG strains. The number of antigen-specific IFNγ-releasing T-cells in the lung and spleen was determined by ELISPOT analysis in the presence of the M. tb Ag85A protein. Data are mean ± SD (n=3/group) and representatives of two independent experiments. Mock, unimmunized. n.s., not statistically significant; *p < 0.05, **p < 0.01 and ***p < 0.001 by two-tailed Student’s t test.
Figure 6
Figure 6
Titration of M. tb Ag85A-specific IgG in C57BL/6 mice immunized with recombinant M. bovis BCG strains. M. tb Ag85A-specific IgG endpoint titers were determined using mouse serum that was collected 4 weeks after M.bovis BCG immunization. Mean reciprocal dilutions are used as the endpoint titer (log10). Data shown are the mean ± SD (n=3/group) and representative of two independent experiments. Mock, unimmunized. n.s., not statistically significant; ***p < 0.001 by two-tailed Student’s t test.
See this image and copyright information in PMC

References

    1. Aaby P., Roth A., Ravn H., Napirna B. M., Rodrigues A., Lisse I. M., et al. . (2011). Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J. Infect. Dis. 204 (2), 245–252. doi: 10.1093/infdis/jir240 - DOI - PubMed
    1. Andersen P., Scriba T. J. (2019). Moving tuberculosis vaccines from theory to practice. Nat. Rev. Immunol. 19 (9), 550–562. doi: 10.1038/s41577-019-0174-z - DOI - PubMed
    1. Arts R. J. W., Moorlag S., Novakovic B., Li Y., Wang S. Y., Oosting M., et al. . (2018). BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity. Cell Host Microbe 23 (1), 89–100.e105. doi: 10.1016/j.chom.2017.12.010 - DOI - PubMed
    1. Babjuk M., Burger M., Capoun O., Cohen D., Compérat E. M., Dominguez Escrig J. L., et al. . (2022). European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur. Urol 81 (1), 75–94. doi: 10.1016/j.eururo.2021.08.010 - DOI - PubMed
    1. Barouch D. H. (2022). Covid-19 vaccines - immunity, variants, boosters. N Engl. J. Med. 387 (11), 1011–1020. doi: 10.1056/NEJMra2206573 - DOI - PMC - PubMed

Publication types